Member Info for EmeraldCarrots

School finishes. Would have us believe she holds some. What a joke that is.

Up 8.16% USA money?

The bottom line is these Companies who now have drugs that can home in on HER-2 positive cancers desperately need a way to find out what the HER-2 status of a persons cancer is before, during and after treatment. Angle Plc are working on just that.

All IMHO.

Astrazeneca have got FDA approval (so they can be used in the USA) for a treatment that targets cancers that are HER2-positive (IHC 3+). From the Astrazeneca RNS:-

"AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.".

From Angle's announcement also this morning:-

"The combination of ANGLE's Parsortix system for harvesting CTCs for analysis, BioView's imaging and analysis technologies, and the new HER2 CTC staining kit under development is intended to provide an easy to use assay based on a simple blood test, providing an up-to-date HER2 status for breast cancer patients on a repeat basis.".

So AstraZeneca, and indeed any Company in the World who's cancer drug targets HER-2 need to know the patients HER-2 status to see if that are suitable and monitor it over time as treatment is given. Angle's contract with Eisai announced by Angle on 2nd Jan is also relevant. See links below.

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html

https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

All IMHO.

To Agl?". It seems to me better ways of testing the HER2 status of cancers are desperateky needed so the people these drugs might benefit can be identified. Angle's announcement this morning shows they are making good progress in this area. Hopefully the likes of Astrazeneca are keeping an eye.......

https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html

Current ways to have a PD-L1 test. See link below.

"There are many ways to do a biopsy. The type of biopsy you have depends on the type of cancer you have and where the tumor is located. In general, a biopsy may be done using:

A hollow needle inserted through your skin. Imaging tests, such as ultrasound, may be used to guide the needle:

1. A fine needle aspiration biopsy uses a very thin needle to remove a sample of cells and/or fluid.

2. A core needle biopsy uses a larger needle to remove a sample.

3. Surgery. Surgery may be done to remove a sample of tissue (an incisional biopsy). In certain cases, the entire tumor will be removed (an excisional biopsy).

4. A scope. Scopes are tools for looking inside your body. They may be inserted through an opening in your body or through a small incision (cut). Special tools may be used with a scope to remove a tissue sample. Examples of scope procedures include bronchoscopy, laparoscopy, colposcopy, and cystoscopy (to examine the inside of the bladder).".

https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/

Until now?

https://www.lse.co.uk/rns/AGL/launch-of-pd-l1-test-to-support-cancer-studies-o8m4cvtjt6ft9a9.html

All IMHO.

"Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial". "First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial". The drug targets the PD-L1 protein!!! On 09 November 2023 Angle announced they have developed an assay to test the PD-L1 status of a persons cancer Circulating Tumour Cells (CTC's) captured by their Parsortix machine. "ANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to investigate real-time patient PD-L1 status for clinical studies. The test is designed for highly accurate, repeatable, and precise results for CTC PD-L1 biomarker expression.". There appears to be a huge potential market for use in future clinical studies plus eventually it could be used to find which cancer patients are suitable candidates for drugs like Astra's Imfinzi at the cancer treatment clinics.

================

Imfinzi 

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses.

==============

https://www.lse.co.uk/rns/AZN/imfinzi-improved-os-pfs-in-limited-stage-sclc-73j5pms6t7uuuuu.html

All IMHO.

That was meant for HE1. I's asked for ot to be deleted from this AGL board.

Hello.

- excuse the pun!

Nice profit though!..

Nice profit though!

Up 34% Ask 0.36p

Agree.

0.34375p trades are buys I believe.

Massive acreage.

Looking good.

Hello.

Hic!

Jackbal.

Now the Parsortix PC-1, the version that is authorised for use by the FDA in the United States for catching Breast Cancer circulating tumour cells for analysis for has been available since roughly September 2022 I think we should get some sales figures in the next results. I think the PC-1 versions are about $50,000 each? Although the RNS to say the FDA clearance was dated 25/05/2022 obviously the paperwork with the machine etc. would have taken some months to sort out so I'm assuming September 2022 was when they became available. That would be very roughly 18 months on the market.

https://angleplc.com/the-parsortix-pc1-system/

Also the amount of cassettes sold would be good (@around $300 each). These are used both with the PC-1 version and the PR-1 version which is for research only. This version costs about $40,000 as I understand it.

The results which should be around 25th April should be extremely interesting. News of some sort of deal with one of the CtDNA analysis Co's would be greatly appreciated!! Also sales of the new assays will be interesting and of course news on the HER2 contract with Bioview which could involve a tie up with a large Pharma Co...................

All IMHO.

Miavoce.

“Around $300 per 1 use cassette how do we know how they have been doing?”

EC that’s a fair point but I lean towards if sales are healthy why not disclose to mkt to improve valuation.

The valuation is the collateral for a company that presently relies on funding so why not uphold it?

Wouldn’t make sense holding back positive stuff like that in these circumstances

=================================================

That sort of information is only disclosed in the results which should be around 21/4/2024.

Only very important information which might affect the bottom line is announced in RNS's between the results.